The Delaware Supreme Court on Wednesday upheld a judgment of more than $80 million against Shire U.S. Holdings Inc. in the case that’s uniquely both gone to trial and been appealed on contingency.

The summary decision came more than two years after shareholders of the acquired company FerroKin Biosciences Inc. proved they were entitled to a missed clinical trial milestone payment.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]